NASDAQ:ACIU - AC Immune Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $12.34 -0.01 (-0.08 %) (As of 07/18/2018 08:00 AM ET)Previous Close$12.35Today's Range$12.00 - $12.8752-Week Range$6.03 - $16.35Volume265,900 shsAverage Volume184,385 shsMarket Capitalization$708.82 millionP/E RatioN/ADividend YieldN/ABeta2.24 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Essex Bio-Technology Limited, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland. Receive ACIU News and Ratings via Email Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ACIU CUSIPN/A Webwww.acimmune.com Phone41-21-345-9121 Debt Debt-to-Equity RatioN/A Current Ratio13.58 Quick Ratio13.58 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.58 million Price / Sales45.46 Cash FlowN/A Price / CashN/A Book Value$2.09 per share Price / Book5.90 Profitability EPS (Most Recent Fiscal Year)($0.30) Net Income$-26,840,000.00 Net Margins-147.54% Return on Equity-25.06% Return on Assets-22.46% Miscellaneous Employees86 Outstanding Shares57,390,000Market Cap$708.82 AC Immune (NASDAQ:ACIU) Frequently Asked Questions What is AC Immune's stock symbol? AC Immune trades on the NASDAQ under the ticker symbol "ACIU." How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) announced its earnings results on Wednesday, May, 2nd. The company reported ($0.20) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.03. The business earned $1.58 million during the quarter, compared to the consensus estimate of $2.18 million. AC Immune had a negative net margin of 147.54% and a negative return on equity of 25.06%. View AC Immune's Earnings History. When is AC Immune's next earnings date? AC Immune is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for AC Immune. What price target have analysts set for ACIU? 2 analysts have issued twelve-month target prices for AC Immune's shares. Their forecasts range from $14.00 to $18.00. On average, they expect AC Immune's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 29.7% from the stock's current price. View Analyst Ratings for AC Immune. What is the consensus analysts' recommendation for AC Immune? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of AC Immune's key competitors? Some companies that are related to AC Immune include Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Emergent Biosolutions (EBS), Supernus Pharmaceuticals (SUPN), Portola Pharmaceuticals (PTLA), TESARO (TSRO), Akcea Therapeutics (AKCA), Clovis Oncology (CLVS), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP), Enanta Pharmaceuticals (ENTA), Xencor (XNCR) and Arena Pharmaceuticals (ARNA). Who are AC Immune's key executives? AC Immune's management team includes the folowing people: Dr. Andrea Pfeifer, Co-Founder, Chief Exec. Officer and Director (Age 60)Mr. Joerg Hornstein, Chief Financial OfficerDr. Andreas Muhs Ph.D., Chief Scientific Officer (Age 56)Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 47)Mr. Gautam Maitra Fil. Lic, Head of Regulatory & External Affairs and Sr. Expert When did AC Immune IPO? (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. Has AC Immune been receiving favorable news coverage? Media coverage about ACIU stock has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AC Immune earned a coverage optimism score of 0.22 on Accern's scale. They also assigned news headlines about the company an impact score of 46.10 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. How do I buy shares of AC Immune? Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AC Immune's stock price today? One share of ACIU stock can currently be purchased for approximately $12.34. How big of a company is AC Immune? AC Immune has a market capitalization of $708.82 million and generates $15.58 million in revenue each year. The company earns $-26,840,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. AC Immune employs 86 workers across the globe. How can I contact AC Immune? AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected] MarketBeat Community Rating for AC Immune (NASDAQ ACIU)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 114 (Vote Outperform)Underperform Votes: 114 (Vote Underperform)Total Votes: 228MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?